Robert W. Baird reaffirmed their outperform rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a research note issued to investors on Tuesday. They currently have a $102.00 price target on the stock.

Several other research analysts also recently weighed in on the stock. RBC Capital Markets reiterated an outperform rating and issued a $106.00 price target (down from $108.00) on shares of Sarepta Therapeutics in a research report on Friday, October 28th. Cowen and Company restated a market perform rating on shares of Sarepta Therapeutics in a research report on Monday, August 15th. Morgan Stanley started coverage on shares of Sarepta Therapeutics in a research report on Thursday, October 27th. They set an equal weight rating and a $53.00 price objective on the stock. Janney Montgomery Scott upgraded shares of Sarepta Therapeutics from a neutral rating to a buy rating and raised their price objective for the company from $30.00 to $65.00 in a research report on Monday, September 19th. Finally, William Blair restated an outperform rating and set a $88.00 price objective on shares of Sarepta Therapeutics in a research report on Sunday, October 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and an average price target of $66.28.

Sarepta Therapeutics (NASDAQ:SRPT) opened at 36.72 on Tuesday. The company has a 50-day moving average of $43.01 and a 200 day moving average of $31.71. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73. The stock’s market capitalization is $2.00 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, October 27th. The company reported ($0.95) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.32) by $0.37. During the same quarter in the prior year, the company earned ($1.25) earnings per share. On average, equities research analysts anticipate that Sarepta Therapeutics will post ($4.31) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Sarepta Therapeutics Inc. (SRPT) Receives “Outperform” Rating from Robert W. Baird” was originally published by Financial Market News and is the sole property of of Financial Market News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The original version of this piece can be accessed at http://www.financial-market-news.com/sarepta-therapeutics-inc-srpt-receives-outperform-rating-from-robert-w-baird/1210480/.

In related news, CEO Edward M. Md Kaye sold 40,179 shares of Sarepta Therapeutics stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $2,410,740.00. Following the completion of the transaction, the chief executive officer now directly owns 117,162 shares of the company’s stock, valued at approximately $7,029,720. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Sandesh Mahatme sold 30,000 shares of Sarepta Therapeutics stock in a transaction dated Monday, October 17th. The stock was sold at an average price of $50.08, for a total transaction of $1,502,400.00. Following the transaction, the insider now directly owns 61,532 shares of the company’s stock, valued at $3,081,522.56. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services Inc bought a new stake in shares of Sarepta Therapeutics during the second quarter worth $302,000. DekaBank Deutsche Girozentrale raised its stake in shares of Sarepta Therapeutics by 26.9% in the second quarter. DekaBank Deutsche Girozentrale now owns 24,733 shares of the company’s stock worth $462,000 after buying an additional 5,250 shares during the last quarter. Emerald Acquisition Ltd. bought a new stake in shares of Sarepta Therapeutics during the second quarter worth $496,000. Swiss National Bank raised its stake in shares of Sarepta Therapeutics by 3.2% in the second quarter. Swiss National Bank now owns 77,100 shares of the company’s stock worth $1,470,000 after buying an additional 2,400 shares during the last quarter. Finally, Quantitative Investment Management LLC bought a new stake in shares of Sarepta Therapeutics during the second quarter worth $3,199,000. 76.99% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.